Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GMI-2093
- Development stage
- Preclinical
- Lead developer
- GlycoMimetics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GMI-2093 is an orally available, small molecule inhibitor of galectin-3, discovered and being developed by GlycoMimetics. Galectin-3 is implicated in the activation of profibrotic factors, promotion of fibroblast proliferation and transformation, and mediation of collagen production. It plays a key role in fibrogenesis across multiple organ systems (liver, kidney, lung, heart) and is also involved in tumor cell transformation, migration, invasion, and metastasis. GMI-2093 is being developed as a therapeutic strategy for tissue fibrosis and certain cancers. As of early 2024–2025 updates, it remains in preclinical development for both fibrosis and cancer[1][2][3][8].
02
Targets
LGALS3 (Galectin-3)
Beyond the preview
Go deeper on GMI-2093.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GMI-2093.